Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Explore this paper's citation graph
Summary
Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence‐free survival and a lower rate of grade 3 or 4 adverse events than adjuant therapy with ipilimumab.
- Type
- article
- Published
- 2017-09-10
- Cited by
- 1,951
- References
- 18
- Access
- Open access
- OpenAlex
- https://openalex.org/W2752227448
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205102454
Keywords
Ipilimumab, Nivolumab, Medicine, Melanoma, Adjuvant
References
- A Phase II Trial of Complete Resection for Stage IV Melanoma: Results of Southwest Oncology Group (SWOG) Clinical Trial S9430
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
- Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
- Final version of 2009 AJCC melanoma staging and classification.
- Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
- Nivolumab in previously untreated melanoma without BRAF mutation.
- Pembrolizumab versus Ipilimumab in Advanced Melanoma.
- Adaptive immune resistance: How cancer protects from immune attack
- Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma
- The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- Phase III trial (EORTC 18071 / CA184-029) of post-operative adjuvant ipilimumab compared to placebo in patients with resected stage III cutaneous melanoma: Health Related Quality of Life (HRQoL) results
- A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry
- PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Cited by
- The Sunbelt Melanoma Trial
- Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma
- Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
- Staging of Cutaneous Melanoma: Is There Room for Further Improvement?
- Pediatric Melanoma and Atypical Melanocytic Neoplasms.
- Immunotherapy in managing metastatic melanoma: which treatment when?
- The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
- Drug therapy: Moving on up — from stage IV into stage III
- Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
- Endocrine side effects of cancer immunotherapy.
- Immune Checkpoint Inhibitors in Melanoma and HIV Infection
- Experimental treatment of patients with disseminated malignant melanoma
- Adjuvant Melanoma Therapy - Head-Spinning Progress.
- Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives
- Moving treatments earlier to move further forward
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- [What's new in oncodermatology?]
- Adjuvante PD-1-Blockade beim Melanom
- Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
- PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Related papers
- Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients
- Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma
- Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
- TNFSF9 is associated with favor tumor immune microenvironment in patients with renal cell carcinoma who are treated with the combination therapy of nivolumab and ipilimumab
- The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
- Japanese real‐world study of sequential nivolumab and ipilimumab treament in melanoma
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
- Nivolumab + ipilimumab ups melanoma response.
- Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
- Cost-effectiveness of nivolumab in advanced melanoma: a drug review